Phase II study of OPAXIO to be revealed

Download PDF Copy

Editorial Checklist

Reviewed

Sep 24 2009

NewsGuard 100/100 Score

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that data from a Phase II study from Brown University of OPAXIO(TM) (paclitaxel poliglumex) combined with standard cisplatin and concurrent radiation in patients with advanced esophageal cancer will be presented by Dr. Howard Safran in an oral Proffered Papers session at the Annual Meeting of the International Society of Gastrointestinal Oncology in Philadelphia, Pennsylvania on Thursday, October 1st at 2:35 p.m. (Eastern time).

Source:

http://www.celltherapeutics.com

Posted in: Drug Trial News | Medical Condition News

Tags: B Cell, Cancer, Cell, Cisplatin, Esophageal Cancer, Oncology, Paclitaxel, T-Cell, Therapeutics

Comments (0)

Download PDF Copy

Suggested Reading

Researchers discover how mutations disrupt protein splicing and cause disease

Researchers discover how mutations disrupt protein splicing and cause disease

Engineered SNIPRs transform CAR T-cell precision for safer cancer therapy

Engineered SNIPRs transform CAR T-cell precision for safer cancer therapy

Barcoding small extracellular vesicles with new CRISPR-based system

Barcoding small extracellular vesicles with new CRISPR-based system

Researchers reveal cellular foundations of functional brain networks in humans

Researchers reveal cellular foundations of functional brain networks in humans

Researchers discover mechanism affecting splicing process in retinal cells

Researchers discover mechanism affecting splicing process in retinal cells

SCimilarity revolutionizes single-cell data analysis with rapid cross-tissue comparisons

SCimilarity revolutionizes single-cell data analysis with rapid cross-tissue comparisons

Mapping human biology: Human Cell Atlas leads a new era in precision medicine

Mapping human biology: Human Cell Atlas leads a new era in precision medicine

Liver cell aging can trigger multi-organ failure

Liver cell aging can trigger multi-organ failure

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Duke-NUS team develops test to monitor engineered T cells in cancer treatment